
ARPA-H Launches Two New Programs
EMBODY: Engineering of Immune Cells Inside the Body
The goal of EMBODY is to radically alter how immune therapies are developed and delivered for life-threatening and chronic conditions by retraining healthy immune cells, and eliminating time, cost and access hurdles.
“By developing agents that target specific immune cell types, essentially providing instructions to cells already active inside your body, we hope to make advanced immunotherapies available close to home for Americans across the country,” said EMBODY Program Manager Daria Fedyukina, Ph.D., in ARPA-H’s recent program announcement.
PRINT (Personalized Regenerative Immunocompetent Nanotechnology Tissue)
PRINT intends to use state-of-the-art bioprinting technology and a regenerative medicine approach to 3D print personalized, on organs that will not require immunosuppressive drugs.
“By starting from multiple different types of cells, we will be creating organs that will be individually matched,” said PRINT Program Manager Ryan Spitler, Ph.D., in ARPA-H’s recent program announcement. “The body will not recognize it as a foreign entity, eliminating the need of immunosuppressive drugs, which has never been done in the history of organ transplantation.”
To learn more about both programs, including how to register for the upcoming Proposers’ Days, visit the EMBODY program page and PRINT program page
- Generic Pharmaceuticals Market To 2035: Growth Fueled by Global Healthcare Cost …
Growth will be supported by an accelerating wave of biologic patent expiries, creating significant value pools in oncology, immunology, and diabetes … - Engineering Trikines | Nature Immunology
Engineering Trikines. Nicholas J. Bernard. Nature Immunology (2026)Cite this article. - The Wistar Institute Announces the Recruitment of Murad Mamedov, Ph.D., to the Center for …
Newswise — PHILADELPHIA — (April 1, 2026) —The Wistar Institute, an international biomedical research leader in cancer, immunology, and infectious … - Biogen Enters $5.6 Billion Agreement to Acquire Apellis Pharmaceuticals | PharmExec
The deal adds two commercialized complement therapies to Biogen's immunology and rare disease portfolio while also laying the groundwork for an … - Biogen to Acquire Apellis for $5.6B to Strengthen Immunology Portfolio – April 1, 2026
BIIB's $5.6B offer to acquire APLS is set to add two key immunology drugs, boosting near-term revenues and strengthening its push into high-growth …

